AU Patent

AU2006255081B2 — Erythropoietin receptor peptide formulations and uses

Assigned to Affymax Inc · Expires 2012-03-29 · 14y expired

What this patent protects

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Phar…

USPTO Abstract

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2006255081B2
Jurisdiction
AU
Classification
—
Expires
2012-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Affymax Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.